Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Methods for the prevention of aggregation of viral components

A virus, enterovirus technology, applied in the direction of viral antigen components, viruses, antiviral agents, etc.

Active Publication Date: 2016-04-20
INTRAVACC LLC
View PDF5 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Antigenic shift, or a series of antigenic drift mutations, could cause a pandemic

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods for the prevention of aggregation of viral components
  • Methods for the prevention of aggregation of viral components
  • Methods for the prevention of aggregation of viral components

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0026] We have surprisingly found that basic amino acids such as arginine and several of its derivatives can be used in different viruses (enveloped (i.e. influenza virus) and non-enveloped (i.e. poliovirus)) in vaccine production and in The (intermediate) viral product prevents aggregate formation during storage and is used to solubilize (disperse / disintegrate) aggregates that have formed. These viruses were derived from different culture systems (embryonized eggs for influenza virus and cell culture medium for poliovirus). Thus, significantly higher recovery of virus production and / or better removal of contaminants while maintaining biologically active product has been achieved. This higher virus yield was unforeseen and provides a significant economic advantage over known virus purification methods.

[0027] It was previously shown that basic amino acids prevent aggregation for monoclonal antibodies (Arakawa T, et al, 2004; US2012264918) and proteins (BaynesBM, 2004 and 20...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a method for prevention and / or reduction of aggregation of viral components.

Description

technical field [0001] The present invention relates to methods of preventing and / or reducing aggregation of viral components. The present invention therefore relates to the field of production and formulation of biopharmaceuticals, as well as to the field of vaccinology. Background technique [0002] Aggregation is a common problem in the production of (bio)pharmaceuticals, especially proteins such as monoclonal antibodies and viruses. More background on protein aggregation can be found in the following review (Wei Wang, 2005). Aggregation can be associated with higher production / manufacturing losses, instability, reduced shelf life, side effects after administration, different immunogenic responses, up to the development of the disease itself (e.g. Alzheimer's disease, Parkinson's disease (Taylor et al. 2002) , prion encephalopathy, and Huntington's disease). Aggregation can be prevented by careful selection of buffers or media used during production (Gu et al., 2003, C...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/13A61K39/15A61K39/145A61K39/155A61K47/18A61K47/22A61P31/14
CPCA61K39/12A61K47/183A61K47/22A61K2039/70C12N7/00C12N2760/16134C12N2770/32323C12N2770/32334A61K39/13A61P31/14C12N2760/16051C12N2760/18051C12N2770/32051C12N2770/32351Y02A50/30A61K39/145A61K2039/5252A61K2039/545C12N2770/32634C12N2770/32651C12N2770/32663
Inventor A·G·范特厄维尔W·A·M·巴克Y·E·托马森
Owner INTRAVACC LLC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com